PROM1 and cancer: Additionally, CD133+ cells demonstrate heightened sensitivity to combination therapies, such as Pa + 4Mu or cisplatin + 4Mu, which significantly impair their clonogenic and spheroid-forming abilities, highlighting the potential of targeting CD133 to eliminate cancer stem-like cells [49,50].